Comments by "Papi Chulo" (@par3me) on "Democrats Are Finalizing A Plan To Lower Insulin Costs" video.

  1. I understand where you’re coming from. I don’t believe you fully understand IP. Let’s say no pharma company could own what they developed. How many would get investors investing in their research? How many new breakthrough drugs would make it to market? How many countries benefit from the drugs that were created in the US over the last 80+ years? Yes, the rich will always benefit first. However, without that, no one would benefit ever. I’d rather wait ten years for a generic than not get one at all. I can already hear the replies. But what if I can’t wait 10 years. That sucks, but removing IP only means the next person on 10 years also won’t have the benefits of new medicines and breakthroughs. Let’s all keep in mind that if Trump didn’t agree to spend an ass ton on vaccines. The pharma companies would not have developed a vaccine. We have a vaccine today because we told them that if they put in the research we’d pain them well. I may not like it, but a its the reality of the situation. Now if we’re taking about our drug prices over Canada and Mexico. That’s a different story. That has everything to do with corrupt politicians and greedy pharma companies. We could end that if we wanted. Trump was moving in that direction before he left office. Feel free to look up your favorite political figure and see how much they have invested in big pharma? You still they they care about your safety or their profits. Drug Pricing and Intellectual Property Law: A Legal Overview for the 116th Congress Intellectual property (IP) rights play an important role in the development and pricing of pharmaceutical products such as prescription drugs and biologics. In order to encourage innovation, IP law grants the rights holder a temporary monopoly on a particular invention or product, potentially enabling him to charge higher-than-competitive prices. IP rights, if sufficiently limited, are typically justified as necessary to allow pharmaceutical manufacturers the ability to recoup substantial costs in research and development, including clinical trials and other tests necessary to obtain regulatory approval from the Food and Drug Administration (FDA). However, because they may operate to deter or delay competition from generic drug and biosimilar manufacturers, IP rights have been criticized as contributing to high prices for pharmaceutical products in the United States.
    1